Argan, Inc. to Announce Fourth Quarter and Fiscal Year-End 2026 Results and Host Conference Call on Thursday, March 26, 2026 Business Wire Argan, Inc. (NYSE: AGX) (“Argan” or the “Company”) today announced that the Company will release its fourth quarter and fiscal year-end 2026 financial results after the market closes on Thursday, March 26, 2026. Management will host a webcast with an accompanying slide presentation and conference call on Thursday, March 26, 2026 at 5:00 p.m. ET. [...]
Onego Bio and Sigma Foods Enter Collaboration to Strengthen Egg Protein Innovation and Supply Resilience Business Wire Onego Bio, a food ingredient company producing non-animal egg protein, and Sigma Foods (“SIGMA”), a leading multinational food company, have entered into a collaboration agreement to evaluate the functionality and commercial potential of Bioalbumen®, a non-animal egg protein made with using precision fermentation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305756400/en/ The [...]
SES: Full Year 2025 Results Business Wire SES S.A. fully consolidates Intelsat from 17 July 2025 and announces financial results for the year ended 31 December 2025 FY25 Performance (€ million) 2025 as reported (1) 2024 as reported (1) ∆ at constant FX (2) 2025 like-for-like (3) 2024 like-for-like (3) ∆ at constant FX (2) Average €/$ FX rate 1.12 1.09 [...]
Allianz Achieves Record Operating Profit of 17.4 Billion Euros – Excellent Start to New Strategic Cycle February 26, 2026 12M 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225107874/en/ Excellent momentum and record operating profit Total business volume rises 8.11 percent and reaches 186.9 billion euros with contributions from all segments Operating profit increases 8.4 percent to 17.4 billion euros, our highest operating profit ever Shareholders’ core net income advances 10.9 [...]
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 February 25, 2026 Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please visit the company’s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast [...]
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 2025 February 25, 2026 Strong margin improvement to 16.3% in FY 2025 Positive growth outlook with continued margin expansion in 2026 New EUR 200 million share buyback
Luxfer Delivers Strong Full-Year 2025 Profitability and Cash Generation February 24, 2026 Portfolio focus and favorable mix drive sustained profitability, enhanced adjusted earnings growth and strong cash flow generation Fourth Quarter 2025 Highlights* Net Sales declined 12.3% to $90.7 million from $103.4 million, while Adjusted Net Sales1 declined 5.5% Net Income of $0.1 million, compared to $3.3 million, and $0.12 per diluted share, with Adjusted Diluted EPS1 of $0.28 down 3.4% from $0.29 Adjusted EBITDA1 of $13.0 million, declined 5.8% Continued execution of previously announced operational excellence initiatives, including the Riverside and Powders Saxonburg centers of excellence, expected to drive improved efficiency and generate approximately $6 million of long-term annual savings Full Year 2025 Highlights* Net Sales declined 1.9% to $384.6 million from $391.9 million, while Adjusted Net Sales1 increased 2.5% Net Income of $13.1 million, or $0.48 per diluted share, compared to $18.3 million and $0.68 per diluted share, with Adjusted Diluted EPS1 of $1.11, up 12.1% from $0.99 Adjusted EBITDA1 of $51.9 million, up 4.2% Delivered strong free cash flow of $26.2 million, reducing net debt to $31.1 million Enhanced portfolio quality and strategic focus following completion of the Graphic Arts sale * Comparative information is relative to prior-year fourth quarter and full year; results exclude discontinued operations 1 Note: Adjusted results exclude Graphic Arts and 2024 legal fee recoveries
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference February 24, 2026 Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 a.m. ET (2:10 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About [...]
Allegion (NYSE: ALLE) Reports Q4, Full-Year 2025 Financial Results, Introduces 2026 Outlook February 17, 2026 High-Single Digit Revenue Growth for the Enterprise and Continued Strength in Americas Non-Residential Quarterly Financial Highlights (All comparisons are year-over-year, unless otherwise noted) Net earnings per share (EPS) of $1.70, up 3.0% compared with $1.65; Adjusted EPS of $1.94, up 4.3% compared with $1.86 Revenues of $1,033.2 million, up 9.3% on a reported basis and up 3.3% on an organic basis Operating margin of 20.3%, compared with 19.5%; Adjusted operating margin of 22.4%, compared with 22.1% Full-Year Financial Highlights (All comparisons are year-over-year, unless otherwise noted) EPS of $7.44, up 9.1% compared with $6.82; Adjusted EPS of $8.14, up 8.1% compared with $7.53 Revenues of $4,067.3 million, up 7.8% on a reported basis and up 4.1% on an organic basis Operating margin of 21.1%, compared with 20.7%; Adjusted operating margin of 23.2%, up 40 basis points compared with 22.8% Available cash flow, which is defined as net cash from operating activities minus capital expenditures, was $685.7 million for 2025, an increase of 17.6% 2026 Full-Year Outlook Highlights Full-year reported revenue growth is estimated to be 5% to 7%, with organic revenue growth estimated to be 2% to 4% Full-year adjusted EPS is estimated to be $8.70 to $8.90 Available cash flow is estimated to be 85% to 95% of adjusted net income
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 February 12, 2026 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The announcement will be followed by [...]